Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects

Saby George, Roberto Pili

Research output: Chapter in Book/Report/Conference proceedingChapter


Management of bone metastases from renal cell carcinoma (RCC) is a challenge compared with some other malignancies. The management involves multidisciplinary approaches. The mainstay of therapy aimed at bone metastases is bisphosphonates and other agents that stabilize osteoclasts. Large trials of bisphosphonates demonstrated benefit in terms of preventing or delaying skeletal-related events and the associated comorbidities related to bone metastases. The limited disease-specific data in RCC suggest that there is benefit from bisphosphonates in delaying skeletal-related events and reducing symptoms. While the role of bisphosphonates remain largely palliative, it is interesting to note that there has been demonstration of direct antitumoral and antiangiogenic effects secondary to bisphosphonate use. Combining tyrosine kinase inhibitors with bisphosphonates is an area that needs to be studied extensively to evaluate the potential for any synergy and any safety issues in RCC patients.

Original languageEnglish (US)
Title of host publicationTargeted Therapies for Renal Cell Carcinoma
PublisherFuture Medicine Ltd.
Number of pages5
ISBN (Print)9781780840024, 9781780841014
StatePublished - Oct 1 2011
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects'. Together they form a unique fingerprint.

Cite this